- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-AREG/ ARB/ CRDGF functional antibody
Anti-AREG/ ARB/ CRDGF functional antibody for cell culture, ELISA & in-vivo assay
Go to AREG/AREG products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T92834-Ab-1/ GM-Tg-hg-T92834-Ab-2 | Anti-Human AREG monoclonal antibody | Human |
| GM-Tg-rg-T92834-Ab-1/ GM-Tg-rg-T92834-Ab-2 | Anti-Rat AREG monoclonal antibody | Rat |
| GM-Tg-mg-T92834-Ab-1/ GM-Tg-mg-T92834-Ab-2 | Anti-Mouse AREG monoclonal antibody | Mouse |
| GM-Tg-cynog-T92834-Ab-1/ GM-Tg-cynog-T92834-Ab-2 | Anti-Cynomolgus/ Rhesus macaque AREG monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T92834-Ab-1/ GM-Tg-felg-T92834-Ab-2 | Anti-Feline AREG monoclonal antibody | Feline |
| GM-Tg-cang-T92834-Ab-1/ GM-Tg-cang-T92834-Ab-2 | Anti-Canine AREG monoclonal antibody | Canine |
| GM-Tg-bovg-T92834-Ab-1/ GM-Tg-bovg-T92834-Ab-2 | Anti-Bovine AREG monoclonal antibody | Bovine |
| GM-Tg-equg-T92834-Ab-1/ GM-Tg-equg-T92834-Ab-2 | Anti-Equine AREG monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T92834-Ab-1/ GM-Tg-hg-T92834-Ab-2; GM-Tg-rg-T92834-Ab-1/ GM-Tg-rg-T92834-Ab-2; GM-Tg-mg-T92834-Ab-1/ GM-Tg-mg-T92834-Ab-2; GM-Tg-cynog-T92834-Ab-1/ GM-Tg-cynog-T92834-Ab-2; GM-Tg-felg-T92834-Ab-1/ GM-Tg-felg-T92834-Ab-2; GM-Tg-cang-T92834-Ab-1/ GM-Tg-cang-T92834-Ab-2; GM-Tg-bovg-T92834-Ab-1/ GM-Tg-bovg-T92834-Ab-2; GM-Tg-equg-T92834-Ab-1/ GM-Tg-equg-T92834-Ab-2 |
| Products Name | Anti-AREG monoclonal antibody |
| Format | mab |
| Target Name | AREG |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-AREG benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T92834-Ag-1 | Recombinant multi-species AREG/ ARB/ CRDGF protein |
| Cytokine | GM-Tg-g-T92834-Ag-1 | amphiregulin (AREG) protein |
| ORF Viral Vector | pGMAP000225 | Human AREG Adenovirus plasmid |
| ORF Viral Vector | pGMLP000520 | human AREG Lentivirus plasmid |
| ORF Viral Vector | vGMLP000520 | human AREG Lentivirus particle |
| ORF Viral Vector | vGMAP000225 | Human AREG Adenovirus particle |
| ORF Viral Vector | pGMLV000735 | house mouse Areg Lentivirus plasmid |
| ORF Viral Vector | pGMLPm000610 | mouse Areg Lentivirus plasmid |
| ORF Viral Vector | vGMLV000735 | house mouse Areg Lentivirus particle |
| ORF Viral Vector | vGMLPm000610 | mouse Areg Lentivirus particle |
Target information
| Target ID | GM-T92834 |
| Target Name | AREG |
| Gene ID | 374,11839,29183,702396,475176,101081041,538751,100050528 |
| Gene Symbol and Synonyms | AR,AREG,AREGB,CRDGF,Mcub,SDGF |
| Uniprot Accession | P15514,P24338 |
| Uniprot Entry Name | AREG_HUMAN,AREG_RAT |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target, Cytokine Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000109321 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: AREG, gene name: AREG, also named as ARB, CRDGF, SDGF, AREG. The protein encoded by this gene is a member of the epidermal growth factor family. It is an autocrine growth factor as well as a mitogen for astrocytes, Schwann cells and fibroblasts. It is related to epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha). The protein interacts with the EGF/TGF-alpha receptor to promote the growth of normal epithelial cells, and it inhibits the growth of certain aggressive carcinoma cell lines. It also functions in mammary gland, oocyte and bone tissue development. This gene is associated with a psoriasis-like skin phenotype, and is also associated with other pathological disorders, including various types of cancers and inflammatory conditions. [provided by RefSeq, Apr 2014].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
